News
Dosing began at Weill Cornell Medical Center in a Phase 2a trial testing foralumab nasal spray in people with nonactive SPMS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback